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The increasing prevalence of serious hospital- 
and community-acquired infections is of great 
concern, with patients dying as a result of emerging 
antimicrobial resistance. Antibiotic-resistant organ-
isms are widespread globally, both in developed and 
developing countries.[1] These organisms are a major threat to public 
health, reduce the effectiveness of empiric antimicrobial treatment 
options, and increase morbidity, mortality and healthcare expenditure. 
A national surveillance system for antimicrobial resistance is essential 
to establish a baseline of the extent of the problem, to follow trends of 
resistance, and to form the basis for recommendations of appropriate 
antimicrobial use to clinicians and other healthcare providers. A 
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Background. The increasing rates of antimicrobial resistance observed in the nosocomial pathogen Klebsiella pneumoniae are of major 
public health concern worldwide. 
Objectives. To describe the antibiotic susceptibility profiles of K. pneumoniae isolates from bacteraemic patients submitted by sentinel 
laboratories in five regions of South Africa from mid-2010 to mid-2012. Molecular methods were used to detect the most commonly found 
extended-spectrum beta-lactamase (ESBL) and carbapenemase resistance genes. 
Methods. Thirteen academic centres serving the public healthcare sector in Gauteng, KwaZulu-Natal, Free State, Limpopo and Western 
Cape provinces submitted K. pneumoniae isolates from patients with bloodstream infections. Vitek 2 and MicroScan instruments were used 
for organism identification and susceptibility testing. Multiplex polymerase chain reactions (PCRs) were used to detect blaCTX-M, blaSHV and 
blaTEM genes in a proportion of the ESBL isolates. All isolates exhibiting reduced susceptibility to carbapenems were PCR tested for blaKPC 
and blaNDM-1 resistance genes. 
Results. Overall, 68.3% of the 2 774 isolates were ESBL-positive, showing resistance to cefotaxime, ceftazidime and cefepime. Furthermore, 
46.5% of all isolates were resistant to ciprofloxacin and 33.1% to piperacillin-tazobactam. The major ESBL genes were abundantly present 
in the sample analysed. Most isolates (95.5%) were susceptible to the carbapenems tested, and no isolates were positive for blaKPC or blaNDM-1. 
There was a trend towards a decrease in susceptibility to most antibiotics. 
Conclusion. The high proportion of ESBL-producing K. pneumoniae isolates observed, and the prevalence of ESBL genes, are of great 
concern. Our findings represent a baseline for further surveillance in SA, and can be used for policy and treatment decisions. 
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national system also controls for differences 
in case selection, data management and 
demo graphic descriptions of regional popu-
lations. To meet this need, a national 
laboratory-based antimicrobial resistance 
surveillance system for nosocomial path-
ogens was established in 2010, which 
included Klebsiella pneumoniae as a sentinel 
organ ism by which to monitor resistance.
K. pneumoniae is an important noso-
comial pathogen, with the highest preva-
lence of resistance to third- and fourth-
gene ration cephalosporins among the 
Enterobacteriaceae. The spread of class 
A or group 2be extended-spectrum beta-
lactamases (ESBLs) in Enterobacteriaceae 
is of public health concern. The most 
frequently detected and clinically important 
ESBLs belong to the TEM, SHV, and CTX-M 
families, and K. pneumoniae commonly 
produces all three groups of enzymes.[2] 
In the past decade, CTX-M enzymes have 
emerged as the most prevalent type. There 
are more than 100 different types, which can 
be broadly divided into five groups based on 
their amino-acid identities: CTX-M1, CTX-
M2, CTX-M8, CTX-M9 and CTX-M25. 
Enzymes are characterised by epidemiological 
differences, and some have even been shown 
to spread beyond the hospital environment 
into the community.[2] Of further public 
health concern are the recent emergence of 
K. pneumoniae strains capable of producing 
carbapenem-hydrolysing enzymes and 
the apparent ease of spread of resistance 
mechanisms by mobile genetic elements.[2] 
There are few published reports on 
national antimicrobial resistance rates of 
K. pneumoniae in South Africa (SA), with 
data primarily emanating from the private 
sector,[3] regional studies with limited 
numbers of local isolates[1] or certain clinical 
settings.[4] To date, molecular data on ESBL 
K. pneumoniae in SA are based on detailed 
studies of small populations. Essack et al.[5] 
examined blaSHV and blaTEM genes in 25 
isolates, and found a high degree of diversity 
in terms of plasmids present, genes detected 
and the combination of genes within isolates. 
In a study of ESBL K. pneumoniae from 
seven countries in 2003, blaTEM-10, blaTEM-12, 
blaTEM-63, various blaSHV-2 and blaSHV-5 types, 
blaCTX-M2 and blaCTX-M3 genes were detected 
in 27 SA isolates.[6] A more recent study on 
53 ESBL clinical pathogens from Pretoria 
detected blaTEM, blaSHV and blaCTX-M-1 
genes, although the contribution of the 31 
K. pneumoniae isolates in this group was 
not specified.[7] This diversity in enzyme 
production and the prolific nature of K. 
pneumoniae as a nosocomial pathogen 
highlight the need for further investigation 
into the genes responsible for these enzymes 
in the SA setting.
In this study, we determined the anti-
biotic susceptibility profiles of K. pneumo-
niae isolates from bacteraemic patients 
with positive blood cultures from sentinel 
sites representing five SA regions. We used 
national laboratory-based surveillance 
data to characterise the third- and fourth-
generation cephalosporin-resistant and 
carba penem-resistant phenotypes and 
genotypes of K. pneumoniae from 2010 to 
2012. 
Methods
Patient selection 
Thirteen academic centres serving the public 
healthcare sector in SA were included, 
and participation was voluntary. The sites 
represented regions in Gauteng, KwaZulu-
Natal, Free State, Limpopo and Western 
Cape provinces. Isolates of K. pneumoniae 
from patients with bloodstream infections 
were submitted, with a 3-week exclusion 
thereafter to avoid duplicate isolates of the 
same organism. 
Phenotypic methods
K. pneumoniae isolates were submitted 
on Dorset transport media. Organism 
identification was confirmed using the 
Vitek 2 GN card (Biomerieux, France). 
Susceptibility testing and determination 
of ESBL phenotype was performed on the 
MicroScan Walkaway (Siemens Healthcare 
Diagnostics, USA), using NM37 panels. 
Categorical results and susceptibility profile 
of each antimicrobial agent tested were 
based on 2012 Clinical Laboratory Standards 
Institute (CLSI) interpretative criteria,[8] the 
European Committee on Antimicrobial 
Susceptibility Testing guidelines[9] and/
or the MicroScan recommendations. The 
MIC50 and MIC90 (minimum inhibitory 
concentrations needed to inhibit the growth 
of 50% and 90% of organisms, respectively) 
were determined. The Agresti-Coull interval 
method was used to calculate confidence 
intervals, and a χ2 test was performed to 
analyse trends in antibiotic susceptibility. 
A p-value of <0.05 was deemed statistically 
significant.
Genotypic methods
Two hundred and seventy ESBL-
producing isolates were randomly selec-
ted (approximately 14% per region) and 
screened for the presence of ESBL genes. 
DNA was extracted from half a loop 
(~2  mm in diameter) of bacterial culture. 
This was resuspended in 400 µl tris-
ethylenediaminetetraacetic acid buffer 
(pH 8.0), vortexed briefly, heated at 95°C for 
25 minutes and pelleted by centrifugation. 
The supernatant was aliquoted and stored at 
–70°C for further use.
The LightCycler 480 instrument (Roche 
Applied Science, Germany) and LightCycler 
480 Probes Master kit (Roche Diagnostics, 
USA) were used for real-time polymerase 
chain reaction (PCR). The blaTEM and blaSHV 
genes were amplified by multiplex real-time 
PCR using the primers shown in Table 1. 
The primers were selected for specificity by 
GenBank comparisons and PCR products 
from control strains were sequenced. The 
limit of detection was determined to be 
750 colony-forming units (cfu)/ml for blaTEM 
and 4 000 cfu/ml for blaSHV. The reaction 
conditions were 0.5 μM primers, 0.2 μM 
probes, denaturation for 95°C for 5 minutes, 
and then 45 cycles of 95°C for 10 seconds, 
55°C for 30 seconds and 72°C for 1 second. 
The blaCTX-M PCR was a multiplex assay 
targeting blaCTX-M groups M1 and M2-9 using 
primer and probe sequences as described 
previously.[10] Detection of blaNDM-1 and blaKPC 
genes was performed on isolates with reduced 
susceptibility to carbapenems as described 
previously.[11] Reduced susceptibility to 
carbapenems was defined according to the 
CLSI guidelines of 2012.[8] Strains from the 
Table 1. Primer and probe sequences for blaTEM and blaSHV gene detection
SHV Forward Primer 5ʹ-CAG CAG GAT CTG GTG GAC TAC T-3ʹ
SHV Reverse Primer 5ʹ-GTC AAG GCG GGT GAC GTT-3ʹ
SHV A Primer 5ʹ-AAG GCG GGT GAC GTT GTC-3ʹ
SHV S Primer 5ʹ-CCG GTC AGC GAA AAA CAC-3ʹ
SHV Probe 5ʹ-Cy5-TCT GGC GCA AAA AGG CAG TCA-BBQ-3ʹ
TEM Forward Primer 5ʹ-AAG TTC TGC TAT GTG GTG CGG TA-3ʹ
TEM Reverse Primer 5ʹ-TGT TAT CAC TCA TGG TTA TGG CAG C-3ʹ
TEM A Primer 5’-GTA AGA TGC TTT TCT GTG ACT GGT GA-3ʹ
TEM S Primer 5ʹ-AGT TCT GCT ATG TGG TGC GGT ATT A-3ʹ
TEM Probe 5ʹ-FAM-TGC GGC GAC CGA GTT GCT CTT-BBQ-3ʹ
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American Type Culture Collection (ATCC) 
or the National Culture Collection Laboratory 
of the National Institute for Communicable 
Diseases were used as positive controls.
Results
A total of 2 774 discrete K. pneumoniae 
isolates were received and included in the 
antimicrobial susceptibility testing over 
the 3-year period. The majority of isolates 
demonstrated an ESBL phenotype (68.3%) 
with marked resistance to third- and fourth-
generation cephalosporins. The distribution 
of isolates according to province, and ESBL 
rates, are shown in Table 2. A breakdown of 
susceptibility by agent for the 3-year period 
is presented in Fig. 1. 
Reduced carbapenem susceptibility was 
noted in only 124 (4.5%) of isolates (Table 2). 
The carbapenemase genes blaNDM-1 and blaKPC 
were not detected in any of the 124 isolates 
and the presence of other carbapenemase-
producing genes was not investigated. 
Susceptibility to aminoglycosides over 
the 3-year period was variable, with 95.3% 
susceptible to amikacin but only 31.1% 
and 31.3% susceptible to tobramycin and 
gentamicin, respectively (Fig. 1). Suscepti-
bility to levofloxacin (75.2%) was higher than 
to ciprofloxacin (53.5%). Sixty-seven (66.9%) 
per cent of all isolates were susceptible to 
piperacillin-tazobactam (MIC50 = 8 µg/ml) 
for the 3 years, and sus ceptibility to cefoxitin 
was high at 87.4% (Table 3). 
Trend analysis was performed on the 
isolates, comparing the susceptibility rates 
between 2010, 2011 and 2012 (Table 4). 
Small but statistically significant declines 
in susceptibility rates were noted for 
many antibiotics, including amoxicillin/
clavulanate, tobramycin, gentamicin, cipro-
floxacin, ceftazidime and cefotaxime.
Molecular characterisation was per-
formed on 270 ESBL-positive isolates. All 
phenotypically ESBL-positive isolates were 
confirmed to possess one or more of the 
blaCTX-M, blaSHV and blaTEM genes, with 93.0% 
of the isolates tested expressing more than 
one resistance gene (Fig. 2). 
Discussion
Gauteng contributed the majority of isolates 
in the study (62.6%), probably because it is 
the most populous province with the largest 
academic centres. The high percentage 
of bacteraemic K. pneumoniae that were 
resistant to third-generation cephalosporins 
(68.3%) is of serious public health concern. 
Rates of resistance in a 2006 study from SA 
private laboratories showed 52% resistance 
to cefuroxime, 46% to ceftriaxone and 
44% to cefepime.[3] A study of resistance 
at seven public sector hospitals between 
2010 and 2012 reported an overall level 
of ESBL detection of 65%.[12] Our study 
shows a similar rate (68.3%) of resistance 
to extended-spectrum cephalosporins. The 
difference between the private and public 
sectors may indicate a dramatic increase in 
development of resistance in the interim, 
and/or a difference in sampling and 
resistance patterns between these sectors. 
Also, because they are referral centres, the 
academic centres that submitted isolates 
in this study potentially contributed a 
disproportionate number of patients who 
were more likely to harbour ESBL isolates. 
Globally, reports show a trend towards an 
increase in resistance of K. pneumoniae to 
third-generation cephalosporins.[13] While 
rates of resistance are low in some countries, 
Table 2. Provinces of submission of K. pneumoniae isolates 2010 - 2012 and 
proportion of isolates found to be ESBL-positive or to have reduced susceptibility 
to carbapenems
Province
Isolates 
submitted 2010 - 
2012, N
ESBL-positive 
isolates 
2010 - 2012, n (%)
Reduced carbapenem
susceptibility, n (%)
Gauteng 1 737 1 207 (69.5) 75 (4.3)
Western Cape 620 414 (66.8) 25 (4.0)
KwaZulu-Natal 268 203 (75.7) 15 (5.6)
Free State 134 59 (44.0) 7 (5.2)
Limpopo 15 12 (80.0) 2 (13.3)
Totals 2 774 1 895 (68.3) 124 (4.5)
ESBL = extended-spectrum beta-lactamase.
Amikacin
Gentamicin
Tobramycin
Amoxicillin/clavulanate
Piperacillin/tazobactam
Cefoxitin
Cefotaxime/cefepime
Ceftazidime
Ciprooxacin
Levooxacin
Ertapenem
Imipenem
Meropenem
Nitrofurantoin
Fosfomycin
Tigecycline*
Trimethoprim/sulfamethoxazole
Colistin
0 10 20 30 40 50 60 70 80 90 100
A
nt
im
ic
ro
bi
al
 a
ge
nt
s
Susceptible, %
Year 2012 Year 2011 Year 2010
87.2
91.8
91
90.6
92.3
91.9
88
91.9
89.3
41.2
42.9
44.7
96.8
98.9
98.1
98.9
96.9
97.2
94.5
97.8
96.1
75.4
74.1
76.1
51.1
50.4
59
24.1
26.2
30.5
24.5
26.4
30.3
86.6
88.2
87.5
64.5
67.8
68.5
27.3
28.9
37.5
28.6
30.2
34.7
30.4
33.3
39.3
94.5
96.7
94.7
 27.6 
27.1
  28.3
Fig. 1. Percentage susceptibility to antimicrobial agents, 2010 - 2012. Confi dence intervals were a 
maximum of ±2% for all antibiotics for each year. Susceptibility percentages for cefotaxime and 
cefepime were identical. (*European Committee on Antimicrobial Susceptibility Testing guidelines.[9])
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e.g. 11.5% in 2010 in the USA,[13] higher rates 
have been observed in other regions.[14]
This laboratory-based surveillance also 
under lines the endemic distribution of all 
three major groups of ESBL genes through-
out five regions of SA. The almost iden-
tical susceptibility pattern to cefotaxime, cef-
tazidime and cefepime suggests that there are 
multiple copies of several ESBL genes in the 
sample, which is supported by the genotypic 
results. A limitation of the study is that the 
genotypic data represent only 14% of K. 
pneumoniae isolates from selected academic 
or referral laboratories, and may not be 
fully representative at a national level. The 
phenotypic data support the genotypic data, 
however, being fairly representative of all 
isolates sampled in this survey. These results 
are also a first indication of the extensive 
prevalence of blaSHV, blaTEM and blaCTX-M genes 
in geographically distinct regions of SA. 
Susceptibility to carbapenems was high, 
with only 4.5% of isolates showing reduced 
susceptibility. However, carbapenem-resis-
tant Enterobacteriaceae have been described 
in SA,[15] and levels of carbapenem resistance 
need to be monitored closely. It must also 
be noted that the breakpoints for ertapenem 
Table 3. Antibiotic MIC50, MIC90 and breakpoints for 2 774 K. pneumoniae isolates
2010 2011 2012
MIC interpretive 
breakpoints (µg/ml)*
Antibiotics MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 S R
Amikacin ≤8 16 ≤8 16 ≤8 16 ≤16 ≥64
Gentamicin >8 >8 >8 >8 >8 >8 ≤4 ≥16
Tobramycin >8 >8 >8 >8 >8 >8 ≤4 ≥16
Amoxicillin/
clavulanate
16/8 >16/8 16/8 >16/8 16/8 >16/8 ≤8/4 ≥32/16
Piperacillin/
tazobactam
≤8 >64 ≤8 >64 ≤8 >64 ≤16/4 ≥128/4
Cefoxitin ≤8 16 ≤8 16 ≤8 16 ≤8 ≥32
Cefotaxime >32 >32 >32 >32 >32 >32 ≤1 ≥4
Ceftazidime 16 >16 16 >16 >16 >16 ≤4 ≥16
Cefepime >16 >16 >16 >16 >16 >16 ≤8 ≥32
Ciprofloxacin ≤0.5 >2 ≤0.5 >2 1 >2 ≤1 ≥4
Levofloxacin ≤1 >4 ≤1 >4 ≤1 >4 ≤2 ≥8
Ertapenem ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≥2
Imipenem ≤2 ≤2 ≤2 ≤2 ≤2 ≤2 ≤1 ≥4
Meropenem ≤1 ≤1 ≤1 ≤1 ≤1 ≤1 ≤1 ≥4
Nitrofurantoin 64 >64 64 >64 64 >64 ≤32 ≥128
Fosfomycin ≤32 >32 ≤32 >32 ≤32 >32 ≤64 ≥256
Tigecycline† ≤1 ≤1 ≤1 ≤1 ≤1 ≤1 ≤1 >2
Trimethoprim/
sulfamethoxazole
>4/76 >4/76 >4/76 >4/76 >4/76 >4/76 ≤2/38 ≥4/76
Colistin† ≤2 ≤2 ≤2 ≤2 ≤2 4 ≤2 ≥2
MIC50  = minimum inhibitory concentrations needed to inhibit the growth of 50% of organisms; MIC90 = minimum inhibitory concentrations needed to inhibit the growth of 90% of organisms; S = susceptible; R = resistant.
*Clinical Laboratory Standards Institute guidelines, 2012.[8] 
†European Committee on Antimicrobial Susceptibility Testing guidelines.[9]
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Fig. 2. Distribution of ESBL genes as percentages in 270 isolates tested. Percentages of the most frequent 
combinations are shown as data labels. (ESBL = extended-spectrum beta-lactamase; FS = Free State; 
GA = Gauteng; KZ = KwaZulu-Natal; LP = Limpopo; WC = Western Cape.)
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have since been revised by the CLSI.[8] A 
limitation of this study is that we only tested 
for blaNDM-1 and blaKPC genes and did not 
investigate for other potential mechanisms 
of carbapenem resistance.
For piperacillin-tazobactam, the MIC50 
was within the susceptible breakpoint 
while the MIC90 was above the resistant 
breakpoint. Overall susceptibility was 
66.9%, and piperacillin-tazobactam may 
therefore be a potentially useful agent for 
treatment. However, there is still debate 
concerning the use of piperacillin-
tazobactam to treat infections with ESBL-
producing Enterobacteriaceae. There is 
some evidence that outcomes may be worse 
if the piperacillin-tazobactam MIC is 8 - 16 
mg/l, with suggestions that if piperacillin-
tazobactam is used to treat organisms with 
these MICs, prolonged infusions or more 
frequent dosing may be needed.[16] 
The 87.4% susceptibility to cefoxitin 
suggests that plasmid-mediated AmpC 
enzymes are not particularly prevalent in 
this sample. The disparity in ciprofloxacin 
and levofloxacin resistance (21.7% diff-
erence) is intriguing and although we do 
not have genotypic data to support it, it may 
represent an increase in quinolone resistance 
mechanisms (e.g. plasmid-mediated mech-
anisms; enzymatic modification) other 
than the conventional target site mutations, 
where one would expect cross-resistance[17] 
as 61.5% ESBL of K. pneumoniae iso lates 
were resistant to ciprofloxacin. 
Among all aminoglycosides, amikacin 
exhibited the best activity, although this 
must be interpreted with caution as the 
stipulated breakpoints are high consid-
ering that this is a concentration-dependent 
agent. The MIC50 and MIC90 of 8 µg/ml 
and 16 µg/ml, respectively, indicate that for 
many isolates the probability of achieving 
adequate serum levels is quite low. 
Overall, the MIC50 and MIC90 to most 
agents have not changed over the 3-year 
period, although the ability to detect smaller 
differences may have been limited by 
the methodological system employed for 
susceptibility testing. The one exception was 
colistin, for which a significant increase in 
MIC90 was noted in 2012 (p=0.001) (Table 
4). This is alarming, as colistin represents 
the mainstay of the treatment of most of our 
extensively drug-resistant Gram-negative 
pathogens (including carbapenem-resistant 
K. pneumoniae).[18] Trends in susceptibility 
showed a significant decrease over the study 
period for most antimicrobial agents, with a 
few exceptions, e.g. piperacillin-tazobactam, 
levofloxacin and tigecycline.
A limitation of this study was that com-
prehensive patient demographic details 
were unavailable, and it was not possible 
to determine accurate trends in patient age, 
ward and gender. This information will be 
obtained in future surveys, allowing for more 
detailed analyses of antimicrobial resistance 
patterns, and how they change over time. 
These surveillance results should be used 
together with hospital-specific data as tools 
in antimicrobial stewardship programmes 
and for the development of empiric therapy 
guidelines for healthcare-associated infec-
tions. Ongoing antimicrobial resistance sur-
v eillance, performed in a systematic and 
standardised manner, could be used as a tool 
to monitor the effectiveness of antimicrobial 
stewardship programmes that have been 
implemented in various centres across the 
country. Moreover, it provides a foundation 
for the systematic surveillance of important 
hospital pathogens that could be expanded 
and enhanced over time.
Conclusion
SA appears to have a relatively high percentage 
of ESBL-producing K. pneumoniae isolates in 
comparison with other geographical regions, 
which is of great concern, and a significant 
increase in ertapenem resistance over the 
surveillance period. This study presents the 
antibiotic resistance patterns of invasive K. 
pneumoniae isolates and gives an indication 
of the prevalence of resistance genes. Our 
findings provide important baseline data for 
further site-specific analysis of K. pneumoniae 
isolates, as well as a platform for enhanced 
surveillance of K. pneumoniae antimicrobial 
resistance in the country. Additionally, 
when analysed in conjunction with patient 
demographic and clinical details these data 
are important for the development of empiric 
therapy guidelines for management of sepsis 
in SA healthcare institutions.
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